Proteasome inhibitor-induced gastrointestinal toxicity

Area of Science:

• Oncology
• Pharmacology
• Gastroenterology

Background:

• Proteasome inhibitors are crucial in cancer therapy.
• Gastrointestinal (GI) toxicities are frequent side effects of proteasome inhibitors.
• Common GI side effects include nausea, vomiting, diarrhea, and constipation.

Purpose of the Study:

• To review existing literature on proteasome inhibitor-induced GI toxicities.
• To provide updates on recent findings in this field.
• To explore potential mechanisms underlying these GI toxicities.

Main Methods:

• Literature review of studies on proteasome inhibitors and GI toxicity.
• Analysis of comparative safety data for different proteasome inhibitors.
• Examination of research on novel oral proteasome inhibitors.

Main Results:

• Carfilzomib shows similar GI toxicity to bortezomib, with less neurotoxicity.
• Oral proteasome inhibitors like ixazomib are under investigation.
• Mechanisms of proteasome inhibitor-induced GI toxicity are still poorly understood.

Conclusions:

• GI toxicities persist with proteasome inhibitor use, especially with combination therapies or oral agents.
• Further research into the pathophysiology of GI toxicity is essential.
• Understanding these mechanisms will improve the safety of current and future proteasome inhibitors.